Current status of human papillomavirus vaccines.
10.7774/cevr.2014.3.2.168
- Author:
Kwang Sung KIM
1
;
Shin Ae PARK
;
Kyung Nam KO
;
Seokjae YI
;
Yang Je CHO
Author Information
1. Eyegene Inc., Seoul, Korea. white@eyegene.co.kr
- Publication Type:Clinical Trial ; Review
- Keywords:
Papillomavirus vaccines;
Virus-like particle vaccines;
Uterine cervical neoplasms;
Clinical trial
- MeSH:
Cervix Uteri;
Condylomata Acuminata;
Female;
Humans;
Papillomavirus Vaccines*;
Risk Factors;
Uterine Cervical Neoplasms;
Vaccines;
Vaccines, Virus-Like Particle
- From:Clinical and Experimental Vaccine Research
2014;3(2):168-175
- CountryRepublic of Korea
- Language:English
-
Abstract:
Cervical cancer is a malignant neoplasm arising from cells that originate in the cervix uteri. It is the second most prevalent cancer among women. It can have several causes; an infection with some type of human papillomavirus (HPV) is the greatest risk factor for cervical cancer. Over 100 types of HPVs have been identified, and more than 40 types of HPVs are typically transmitted through sexual contact and infect the anogenital region. Among these, a number of HPVs types, containing types 16 and 18, are classified as "high-risk" HPVs that can cause cervical cancer. The HPVs vaccine prevents infection with certain species of HPVs associated with the development of cervical cancer, genital warts, and some less common cancers. Two HPVs vaccines are currently on the global market: quadrivalent HPVs vaccine and bivalent HPV vaccine that use virus-like particles as a vaccine antigen. This review discusses the current status of HPVs vaccines on the global market, clinical trials, and the future of HPVs vaccine development.
